首页> 外文OA文献 >Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose–response manner: a randomized, double-blind, placebo-controlled study

【2h】

Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose–response manner: a randomized, double-blind, placebo-controlled study

机译：Relugolix是一种口服促性腺激素释放激素受体拮抗剂，以剂量反应方式减少子宫内膜异位症相关的疼痛：随机，双盲，安慰剂对照研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Yutaka Osuga; Yoshifumi Seki; Masataka Tanimoto; Takeru Kusumoto; Kentarou Kudou; Naoki Terakawa;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women [J] . Osuga Yutaka, Enya Kazuaki, Kudou Kentarou, Fertility and Sterility: Official Journal of the American Fertility Society, Pacific Coast Fertility Society, and the Canadian Fertility and Andrology Society . 2019,第5期

机译：Relugolix，一种新型口服促性腺激素 - 释放激素拮抗剂，治疗与子宫肌瘤相关的疼痛症状：日本女性的随机，安慰剂控制，第3期第3期研究
2. Oral V receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study. [J] . Thuluvath PJ, Maheshwari A, Wong F, Alimentary pharmacology & therapeutics. . 2006,第6期

机译：肝硬化和腹水患者的口服V受体拮抗剂（RWJ-351647）：一项随机，双盲，安慰剂对照，单次递增剂量的研究。
3. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. [J] . Webster L, Jansen JP, Peppin J, Pain. . 2008,第2期

机译：Alvimopan，一种外周作用的阿片类药物受体（PAM-OR）拮抗剂，用于治疗阿片类药物引起的肠功能障碍：一项针对服用阿片类药物治疗慢性非糖尿病患者的随机，双盲，安慰剂对照剂量寻找研究的结果癌痛。
4. MULTI-CENTER, PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED STUDY OF ORAL TOCERANIB PHOSPHATE (PALLADIATM, SU11654), A RECEPTOR TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF DOGS WITH RECURRENT MAS [C] . Cheryl L London, Carolyn J Henry, Anthony W Rusk, Annual conference of the Veterinary Cancer Society . 2008

机译：多中心，安慰剂对照，双盲，随机研究口服Toceranib磷酸盐（Palladia TM，SU11654），受体酪氨酸激酶抑制剂，用于治疗经常性MAS的狗
5. A randomized, double-blind, placebo-controlled phase II trial to examine the effect of polyphenon E on endogenous hormone levels [D] . Ling, Chen 2009

机译：一项随机，双盲，安慰剂对照的II期临床试验，用于研究多肽E对内源激素水平的影响
6. OR11-03 NT-814 a Non-Hormonal Dual Neurokinin 13 Receptor Antagonist Markedly Improves Vasomotor Symptoms in Post-Menopausal Women; Results of a Randomised Double-Blind Placebo-Controlled Dose-Finding Study (SWITCH-1) [O] . James Simon, Richard A Anderson, Elizabeth Ballantyne, 2020

机译：OR11-03 NT-814非激素双神经蛋白13受体拮抗剂显着改善绝经后妇女中的血管传道症状;随机双盲安慰剂控制剂量查找研究的结果（Switch-1）
7. Elagolix, an oral gonadotropin-releasing hormone antagonist, for the management of endometriosis-associated pain: safety and efficacy results from two double-blind, randomized, placebo-controlled studies [O] . H.S. Taylor, L.C. Giudice, B.A. Lessey, 2016

机译：Elagolix，口服促性腺激素 - 释放激素拮抗剂，用于治疗子宫内膜异位症相关的疼痛：安全性和有效性来自两个双盲，随机，安慰剂对照研究

Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose–response manner: a randomized, double-blind, placebo-controlled study

著录项

引文网络

相似文献

相关主题

期刊订阅